Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 1371 results for patients and public

  1. Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]

    In development [GID-TA11384] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  2. Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]

    In development [GID-TA11090] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]

    In development [GID-TA11389] Expected publication date: 12 June 2024

    Technology appraisal guidance
    In development

  4. Eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis [ID6337]

    In development [GID-TA11392] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  5. Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130]

    In development [GID-HST10059] Expected publication date: 18 December 2024

    Highly specialised technologies guidance
    In development

  6. Pegzilarginase for treating arginase-1 deficiency [ID4029]

    In development [GID-HST10054] Expected publication date: 30 October 2024

    Highly specialised technologies guidance
    In development

  7. Sparsentan for treating primary IgA nephropathy ID6308

    In development [GID-TA11359] Expected publication date: 11 December 2024

    Technology appraisal guidance
    In development

  8. Iptacopan for treating paroxysmal nocturnal haemoglobinuria [ID6176]

    In development [GID-TA11132] Expected publication date: 26 June 2024

    Technology appraisal guidance
    In development

  9. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]

    In development [GID-TA11391] Expected publication date: 23 October 2024

    Technology appraisal guidance
    In development

  10. Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

    In development [GID-TA10165] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    In development [GID-TA11117] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  12. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development [GID-TA11386] Expected publication date: 04 December 2024

    Technology appraisal guidance
    In development

  13. Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]

    In development [GID-TA10980] Expected publication date: 17 July 2024

    Technology appraisal guidance
    In development

  14. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

    In development [GID-TA11369] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  15. Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]

    In development [GID-TA10962] Expected publication date: 17 July 2024

    Technology appraisal guidance
    In development